REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on the development of OCR-002 for the treatment and prevention of hepatic encephalopathy (HE), a debilitating complication of liver disease and significant burden on the healthcare system, today reported financial results for the quarter ended June 30, 2017.
"We've enjoyed a busy quarter preparing to meet with the U.S. Food and Drug Administration (FDA) later this year regarding the design of the next clinical study for our ammonia scavenger OCR-002," said Linda Grais, M.D., Chief Executive Officer of Ocera. "The meeting with FDA will focus on the intravenous formulation of OCR-002 which we are developing to treat hospitalized patients with elevated ammonia and neurocognitive symptoms of HE. In addition, our Phase 2a study with oral OCR-002 in patients with cirrhosis is progressing well, and we remain on track to report top-line results by the end of the year."
Select Second Quarter Financial Results
Ocera reiterates its previous guidance and expects net use of cash for 2017 to be in the range of $24.0 million to $27.0 million, including $3.1 million in scheduled principal repayments on notes payable, and reiterates its expectation that it will have sufficient cash to fund operations into the second quarter of 2018 based on its current operating plan.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
This press release contains "forward-looking" statements, including, without limitation, all statements related to the OCR-002 clinical development program, including but not limited to the potential benefits of OCR-002 to help patients with hepatic encephalopathy, our ability to identify a development path forward for OCR-002, our expected timing for release of clinical data, the timing and nature of our future clinical development plans, and the company's financial projections. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "expected," "hope," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ocera's current expectations. Forward-looking statements involve risks and uncertainties and Ocera's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that we may be unable to raise sufficient capital or consummate other strategic transactions to enable the continued development of OCR-002, and those risks and uncertainties discussed under the heading "Risk Factors" in Ocera's Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Ocera undertakes no duty to update this information unless required by law.
|Ocera Therapeutics, Inc.|
|Condensed Consolidated Statement of Operations|
|(In thousands, except per share data)|
|Three Months Ended|
|Six Months Ended|
|Research and development||3,409||3,909||7,313||8,656|
|General and administrative||2,500||2,970||5,024||5,524|
|Total operating expenses||5,909||6,879||12,337||14,180|
|Loss from operations||(5,909||)||(6,853||)||(12,337||)||(14,121||)|
|Interest expense, net||(224||)||(250||)||(479||)||(496||)|
|Net loss per share, basic and diluted||$||(0.23||)||$||(0.33||)||$||(0.51||)||$||(0.69||)|
|Shares used to compute net loss per share, basic and diluted||26,413,839||21,552,089||25,232,178||21,248,027|
|Ocera Therapeutics, Inc.|
|Condensed Consolidated Balance Sheets|
|June 30,||December 31,|
|Cash, cash equivalents and marketable securities||$||20,562||$||28,360|
|Working capital, excluding notes payable||16,902||24,890|
|Total stockholders' equity||$||9,268||$||15,737|
Susan Sharpe Ocera Therapeutics, Inc. email@example.com 919-328-1109